Aptus Biotech 

Aptamers for improved cancer therapy: a reality come true


Victor M. Gonzalez (See Profile)


Cancer therapeutics


Prototyping, preclinical



AptaMNK our therapeutic drug candidate for breast cancer based on aptamer technology with exclusive rights for Aptus

AptaMNK reduces the tumor size, cell proliferation and number of metastasis in animal models

Aptus is an established company with an experienced team of scientists-entrepreneurs and a track record in the field

Background of success: first Spanish venture to bring an aptamer-based drug (ischemic stroke) to clinical trials

Aptamers: a novel technology in pharmacology with higher stability and improved affinity as an alternative to antibodies

This information is confidential, do not share or copy.

Under evaluation at least till: 30th March

If you want to have more information or you want to review the project, you have to login or register


©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

Aviso de cookies

Log in with your credentials


Forgot your details?

Create Account

Skip to toolbar